复宏汉霖全球化:4年内,在美获批至少8款产品

21世纪经济报道
21 Apr

“至今,我们已经为全球75万名患者提供治疗方案和医疗支持。”  近日,复宏汉霖举办2025全球研发日(R&D Day)活动,复宏汉霖执行董事兼首席执行官朱俊打趣道,之前做医生的时候,一年只能看1000个病人,要活到750岁,才能看75万个患者。  “一位患者的年治疗费用最少3万,累计销售额超过200亿元。”朱俊表示。  2024年,已上市的6款产品,合计为复宏汉霖带来近50亿元销售收入,带动公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10